Over the last six years, a venture capital team run out of pharmaceutical giant Bayer invested roughly $1.5 billion into small biotech startups.
Now, it’s ramping up. The firm plans to invest a nearly identical pot of money — this time, $1.3 billion — in half the time.
Bayer launched its venture arm, Leaps by Bayer, in 2015. The team scouts out startups that the drugmaker could invest in and potentially make a bit of money. But more importantly, its mandate is to find biotech and agriculture startups that might one day make for interesting R&D partners, or acquisition targets.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
